Pasithea therapeutics announces positive safety review committee (src) recommendation from its ongoing phase 1 clinical trial of pas-004 in advanced cancer

-- src recommended that the trial escalate to the next dose level of 15mg capsule -- -- no dose-limiting toxicities (dlts) observed to date -- -- no rash observed to date -- miami, nov. 20, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced that the external safety review committee recommended proceeding to cohort 4, 15mg capsule, without modifications. this recommendation was based on the absence of any dose limiting toxicities (dlt's).
KTTA Ratings Summary
KTTA Quant Ranking